Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock
| Autor: | Angelo M. Dell’Aquila, Matteo Pettinari, Vito G. Ruggieri, Hakeem Yusuff, S. Zipfel, Antonio Loforte, Fausto Biancari, Henryk Welp, Dieter De Keyzer, Giovanni Mariscalco, Magnus Dalén, Khalid Alkhamees, Andrea Perrotti, Dario Di Perna, Andrea Lechiancole, Kristján Jónsson, Antonio Fiore, Marek Pol, Giuseppe Gatti, Thomas Fux, Karl Bounader, Daniele Maselli, Marco Gabrielli, Sigurdur Ragnarsson, Tatu Juvonen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Shock Cardiogenic 030204 cardiovascular system & hematology 03 medical and health sciences Extracorporeal Membrane Oxygenation 0302 clinical medicine 030202 anesthesiology Interquartile range Extracorporeal membrane oxygenation Hospital discharge Humans Medicine Weaning In patient Hospital Mortality Registries Aged Retrospective Studies business.industry Cardiogenic shock Middle Aged medicine.disease University hospital 3. Good health Cardiac surgery Treatment Outcome surgical procedures operative Anesthesiology and Pain Medicine cardiac surgery complications ECMO extracorporeal membrane oxygenation multiple cannulation survival Anesthesia Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of Cardiothoracic and Vascular Anesthesia. 35:3620-3625 |
| ISSN: | 1053-0770 |
| DOI: | 10.1053/j.jvca.2021.03.001 |
| Popis: | Objective Data on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival. Design Retrospective analysis of an international registry. Setting Multicenter study, tertiary university hospitals. Participants Data on adult PCS patients receiving a second run of VA-ECMO. Measurements and Main Results A total of 674 patients with a mean age of 62.9 ± 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was 135 hours (interquartile range [IQR] 61-226) in patients who did not require a VA-ECMO rerun. In the rerun VA-ECMO group the median overall duration of VA-ECMO therapy was 183 hours (IQR 107-344), and the median duration of the first run was 114 hours (IQR 66-169). Nine (42.9%) of the patients who required a second run of VA-ECMO died during VA-ECMO therapy, whereas five (23.8%) survived to hospital discharge. No differences between patients treated with single or second VA-ECMO runs were observed in terms of hospital mortality and late survival. In patients requiring a second VA-ECMO run, the actuarial survival estimates at three and 12 months after VA-ECMO weaning were 23.8% ± 9.3% and 19.6% ± 6.4%, respectively. Conclusions Repeat VA-ECMO therapy is a valid treatment strategy for PCS patients. Early and late survivals are similar between patients who have undergone a single or second run of VA-ECMO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect